FindTrial
Sign In

Pilot study RCT anti-NGF Adalimumab versus placebo in fasciotomy Dupuytren contracture

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2023-503701-11-00
Acronym
S67402
Enrollment
30
Registered
2023-07-05
Start date
2023-10-16
Completion date
Unknown
Last updated
2023-12-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dupuytren Disease

Brief summary

Obtain a minimum increase of 10° correction of the finger extension lack in the treatment group versus the placebo.

Detailed description

Recurrence Rate, QuickDASH, Pain score: Visual Analogue Scale, Patient satisfaction: Visual Analogue Scale

Interventions

DRUGADALIMUMAB
DRUGSALINE

Sponsors

UZ Leuven, UZ Leuven
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Obtain a minimum increase of 10° correction of the finger extension lack in the treatment group versus the placebo.—

Secondary

MeasureTime frame
Recurrence Rate, QuickDASH, Pain score: Visual Analogue Scale, Patient satisfaction: Visual Analogue Scale—

Countries

Belgium

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026